Author:
Bashir Waleed,Shahzadi Sana
Abstract
The incidence of Alzheimer’s disease (AD) is increasing day by day worldwide, which results in a poor quality of life. Early diagnosis and treatment of AD is necessary to suppress the progression of the disease. Conventional treatments have several limitations due to the protective blood-brain barrier. In this review, we described a nanoparticle-based approach to crossing the blood-brain barrier for AD detection and treatment. Nanoparticles encapsulate the anti-AD drug and are directed to the target tissues where controlled release of the drug takes place. There are various types of nanoparticles that are used to encapsulate drugs, including solid-based nanoparticles, liposomes, nanoemulsions, iron NPs, cerium NPs, selenium NPs, and gold NPs. In this review, we have described the use of different nanoparticles as nanomedicine. Nanoparticles are also coated with proteins and antibodies for efficient release of drugs. This review aims to provide clinical insights and the importance of nanotechnology in theranostics and describes how nanomedicine has revolutionized the drug delivery approach for AD treatment
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference54 articles.
1. Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients;Abbas;Polymers,2021
2. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. Science Translational Medicine. 2014;6(226).
3. CDC. What Is Alzheimer's Disease? 2021.
4. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics;Tiwari;International Journal of Nanomedicine,2019
5. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors;Kocahan;Clinical Psychopharmacology and Neuroscience,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献